Related Experiment Video
Updated: Oct 20, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Temporal trends of lipid control in very high cardiovascular risk patients
Paulo Maia Araújo1, Alzira Nunes2, Sofia Torres2
1Centro Hospitalar Universitario de São João, Porto, Portugal.
Insights
Despite European guidelines for very high cardiovascular risk (CVR) patients recommending a low-density lipoprotein cholesterol (LDL-C) target, lipid control remains inadequate. This study shows minimal improvement in lipid-lowering therapy (LLT) use and unchanged control rates over five years.
Area of Science:
- Cardiology
- Public Health
- Pharmacotherapy
Background:
- European guidelines since 2011 set a <70 mg/dl LDL-C target for very high CVR patients.
- Registries indicate suboptimal achievement of these LDL-C goals.
- This highlights a persistent gap in cardiovascular risk management.
Purpose of the Study:
- To evaluate trends in lipid-lowering therapy (LLT) use.
- To assess the attainment of adequate lipid control in very high CVR patients.
- To analyze changes from 2011/2012 to 2016/2017 following guideline implementation.
Main Methods:
- Retrospective observational study of very high CVR patients.
- Comparison of two periods: 2011/2012 and 2016/2017.
- Analysis of lipid values, LLT, and control rates.
Main Results:
- 33.7% of patients were not on LLT; prescription rates showed only slight improvement.
- High-intensity LLT use increased significantly (6.4% to 24.0%), but did not improve control.
- Overall adequate LDL-C control was 24.4%, with no significant change between periods.
Conclusions:
- Specific LDL-C targets remain unmet for most very high CVR patients.
- LLT prescription and adequate lipid control rates showed minimal improvement over five years.
- Further strategies are needed to optimize lipid management in this high-risk population.
Introduction:
Since 2011, the European guidelines have included a specific low-density lipoprotein cholesterol (LDL-C) target, <70 mg/dl, for very high cardiovascular risk (CVR) patients. However, registries have shown unsatisfactory results in obtaining this level of adequate lipid control.
Objectives:
To assess temporal trends in the use of lipid-lowering therapy (LLT) and attainment of adequate control in very high CVR patients since 2011.
Methods:
We performed a retrospective observational study including very high CVR patients admitted in two periods: the first two years since the 2011 guidelines (2011/2012) and five years later (2016/2017). Lipid values, LLT, clinical variables and adequate lipid control rates were analyzed.
Results:
A total of 1314 patients were reviewed (2011/2012: 638; 2016/2017: 676). Overall, 443 patients (33.7%) were not under LLT and only a slight improvement in drug prescription was observed from 2011/2012 to 2016/2017. In LLT users, the proportion of high-intensity LLT increased significantly in the later years (6.4% vs. 24.0%; p<0.001), but this was not associated with adequate lipid control. Overall, mean LDL-C was 95.4±37.2 mg/dl and adequate control was achieved in 320 patients (24.4%), without significant differences between 2011/2012 and 2016/2017 (p=0.282). Independent predictors of adequate control were male gender, older age, diabetes, chronic kidney disease, prior acute coronary syndrome, prior stroke and LLT, while stable coronary artery disease was associated with higher risk of failure.
Conclusion:
Even after the introduction of specific LDL-C targets, these are still not reached in most patients. Over a five-year period, LLT prescription only improved slightly, while adequate lipid control rates remained unchanged.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipids: Dietary Sources and Requirements

